Market News & Trends
Hebei Changshan Biochem Pharma & Albumedix Enter Development Agreement
Albumedix and Hebei Changshan Biochem Pharma Co. recently announced they have entered into a supply agreement for the development of a novel type II diabetes…
New Company Created to Develop Novel Technology to Treat Diabetes
The Cell and Gene Therapy Catapult (CGT) and University of Aberdeen, UK, recently announced the creation of Islexa, a new company developing a novel technology…
Vifor Pharma Licenses Rights to Commercialize ChemoCentryx’s Orally Administered Complement 5aR Inhibitor
Vifor Pharma and ChemoCentryx, Inc. recently announced that Vifor Pharma has licensed rights to commercialize CCX168, a Complement 5a Receptor (C5aR) inhibitor ready for Phase…
Vetter is a Winner of AbbVie TRIUMPH AWARD
AbbVie, one of the world’s leading biopharmaceutical companies has awarded Vetter, a leading contract manufacturing and development organization (CDMO), the TRIUMPH AWARD for 2015. The…
LDC & Boehringer Ingelheim Join Forces to Discover Novel Approach for Schizophrenia Treatment
The Lead Discovery Center GmbH (LDC), Max Planck Innovation GmbH and Boehringer Ingelheim International GmbH have signed an agreement providing Boehringer Ingelheim with the option…
Incyte & Ariad Announce Acquisition & Licensing Agreements
Incyte Corporation and ARIAD Pharmaceuticals, Inc. recently announced the entry into a definitive agreement for Incyte to acquire ARIAD’s European operations. At the close of…
Immune Design & Gritstone Oncology Announce Clinical Collaboration
Immune Design and Gritstone Oncology recently announced a clinical collaboration for development of novel, personalized immunotherapies combining both companies’ leading technologies. The collaboration will involve…
Alize Pharma II Acquired by Jazz Pharmaceuticals
Alizé Pharma II recently announced that a subsidiary of Jazz Pharmaceuticals plc has acquired 100% of its shares. This all-cash transaction closed in March 2016.…
Ajinomoto Althea, Inc. Announces Issuance of New US Patent for Manufacturing of Crystal Monoclonal Antibodies
SAN DIEGO, CA, May 17, 2016 -- Ajinomoto Althea Inc., a leading provider of biotherapeutic contract development and manufacturing services, today announced that the United…
Capsugel Expands Micro-Dosing Services to Help Accelerate Customers' Product Development Timelines
Morristown, N.J., May 16, 2016 – Capsugel, a global leader in delivering high-quality, innovative dosage forms and solutions, today announced that it is expanding its…
Aptar Pharma's Preservative-Free Multi-Dose Ophthalmic Squeeze Dispenser Launched in US
Aptar Pharma, a global solution provider of innovative and proven aerosol, injection and spray delivery systems for biotech, healthcare and pharma products, has partnered with…
Dublin-Based Innopharma Technology Announces Strategic Collaboration With Glatt
Dublin-based Innopharma Technology and Glatt (India) Systems Pvt. Ltd. have recently announced a strategic collaboration that is set to reduce product manufacturing costs…
Disease-Modifying Drugs Will Propel Huntington’s Disease Market to $2.6 Billion
The Huntington’s disease market will rise from around $252.6 million in 2014 to over $2.6 billion in 2024, representing a huge Compound Annual Growth Rate…
Opiant Pharmaceuticals' Partner Submits New Drug Submission
Opiant Pharmaceuticals, Inc. recently announced that its commercial partner for naloxone nasal spray for the emergency reversal of opioid overdose, Adapt Pharma Limited, has submitted…
MilliporeSigma Builds on Leading Viral & Gene Therapy Service Offering
MilliporeSigma recently announced an expansion of its Carlsbad, California facility to meet growing demand for viral and gene therapy products. Scheduled for completion in 2016,…
Merus Announces First Patient Dosed in Phase I/II Trial
Merus B.V. recently announced that the first patient has been dosed in the company’s Phase I/II clinical trial evaluating MCLA-117 as a potential treatment of…
Cellular Immunotherapies Represent Long-Term Opportunity in Immuno-Oncology Space
While cellular immunotherapies, which encompass dendritic cell therapy and chimeric antigen receptor T-cell (CAR-T) therapy, are expected to show promising results in combination treatments in…
CEL-SCI Reports Record Monthly Patient Enrollment for Phase III Head & Neck Cancer Trial
CEL-SCI Corporation recently announced that during the month of April, it has enrolled 41 patients in its ongoing Phase III trial of its investigational immunotherapy…
Alder BioPharmaceuticals Licenses Clazakizumab Rights
Alder BioPharmaceuticals, Inc. and Vitaeris Inc. recently announced that Alder has licensed the exclusive worldwide rights to clazakizumab to Vitaeris. In exchange for the rights…
Heart Failure Market to Soar to $11.8 Billion by 2025
The heart failure market is set to rise from around $3.2 billion in 2015 to $11.8 billion by 2025, representing a compound annual growth rate…
